{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T23:24:49Z","timestamp":1790119489255,"version":"4.0.1"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T00:00:00Z","timestamp":1548115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.03071","type":"journal-article","created":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T21:00:02Z","timestamp":1548190802000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":56,"title":["Protection Against Marburg Virus Using a Recombinant VSV-Vaccine Depends on T and B Cell Activation"],"prefix":"10.3389","volume":"9","author":[{"given":"Andrea","family":"Marzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea R.","family":"Menicucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Engelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Callison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva J.","family":"Horne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Feldmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Jankeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Feldmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilhem","family":"Messaoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,1,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.2217\/fvl.11.79","article-title":"Clinical aspects of Marburg hemorrhagic fever","volume":"6","author":"Mehedi","year":"2011","journal-title":"Fut Virol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S0140-6736(67)90621-6","article-title":"Fatal human disease from vervet monkeys","volume":"2","author":"Smith","year":"1967","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1126\/science.161.3848.1364-a","article-title":"Green monkey agent of disease","volume":"161","author":"Kissling","year":"1968","journal-title":"Science"},{"key":"B4","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1126\/science.160.3830.888","article-title":"Agent of disease contracted from green monkeys","volume":"160","author":"Kissling","year":"1968","journal-title":"Science"},{"key":"B5","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1055\/s-0028-1105098","article-title":"On the hitherto unknown, in monkeys originating infectious disease: Marburg virus disease","volume":"93","author":"Martini","year":"1968","journal-title":"Dtsch Med Wochenschr."},{"key":"B6","doi-asserted-by":"publisher","first-page":"4933","DOI":"10.1128\/JVI.74.10.4933-4937.2000","article-title":"Distinct mechanisms of entry by envelope glycoproteins of Marburg and Ebola (Zaire) viruses","volume":"74","author":"Chan","year":"2000","journal-title":"J Virol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"S1021","DOI":"10.1093\/infdis\/jir339","article-title":"Pathogenesis of Marburg hemorrhagic fever in cynomolgus macaques","volume":"204","author":"Hensley","year":"2011","journal-title":"J Infect Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nrd.2018.73","article-title":"Post-exposure treatments for Ebola and Marburg virus infections","volume":"17","author":"Cross","year":"2018","journal-title":"Nat Rev Drug Discov."},{"key":"B9","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s11262-017-1455-x","article-title":"Ebola and Marburg virus vaccines","volume":"53","author":"Reynolds","year":"2017","journal-title":"Virus Genes"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2157-2526-S1-004","DOI":"10.4172\/2157-2526.S1-004","article-title":"Vesicular Stomatitis Virus-Based Vaccines for Prophylaxis and Treatment of Filovirus Infections","author":"Marzi","year":"2011","journal-title":"J Bioterror Biodef"},{"key":"B11","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/nm1258","article-title":"Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses","volume":"11","author":"Jones","year":"2005","journal-title":"Nat Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"9659","DOI":"10.1128\/JVI.00959-06","article-title":"Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine","volume":"80","author":"Daddario-Dicaprio","year":"2006","journal-title":"J Virol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e94355","DOI":"10.1371\/journal.pone.0094355","article-title":"Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates","volume":"9","author":"Mire","year":"2014","journal-title":"PLoS ONE"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S0140-6736(06)68546-2","article-title":"Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment","volume":"367","author":"Daddario-Dicaprio","year":"2006","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.3201\/eid1607.100159","article-title":"Postexposure treatment of Marburg virus infection","volume":"16","author":"Geisbert","year":"2010","journal-title":"Emerg Infect Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e1567","DOI":"10.1371\/journal.pntd.0001567","article-title":"Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates","volume":"6","author":"Mire","year":"2012","journal-title":"PLoS Negl Trop Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"S404","DOI":"10.1093\/infdis\/jiv188","article-title":"Stat1-Deficient mice are not an appropriate model for efficacy testing of recombinant vesicular stomatitis virus-based filovirus vaccines","volume":"212","author":"Marzi","year":"2015","journal-title":"J Infect Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"S234","DOI":"10.1093\/infdis\/jiv095","article-title":"Immune response to marburg virus angola infection in nonhuman primates","volume":"212","author":"Fernando","year":"2015","journal-title":"J Infect Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1128\/CVI.00170-10","article-title":"Enzyme-linked immunosorbent assay for detection of filovirus species-specific antibodies","volume":"17","author":"Nakayama","year":"2010","journal-title":"Clin Vaccine Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1186\/s12859-016-1241-0","article-title":"systemPipeR: NGS workflow and report generation environment","volume":"17","author":"Backman","year":"2016","journal-title":"BMC Bioinformatics"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1073\/pnas.1209591110","article-title":"Antibodies are necessary for rVSV\/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates","volume":"110","author":"Marzi","year":"2013","journal-title":"Proc Natl Acad Sci USA."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1038\/ni1008-1091","article-title":"Immunological Genome Project C. The Immunological genome project: networks of gene expression in immune cells","volume":"9","author":"Heng","year":"2008","journal-title":"Nat Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"6894","DOI":"10.1016\/j.vaccine.2008.09.082","article-title":"Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses","volume":"26","author":"Geisbert","year":"2008","journal-title":"Vaccine"},{"key":"B25","doi-asserted-by":"publisher","first-page":"7296","DOI":"10.1128\/JVI.00561-09","article-title":"Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus","volume":"83","author":"Geisbert","year":"2009","journal-title":"J Virol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"S1075","DOI":"10.1093\/infdis\/jir349","article-title":"Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections","volume":"3","author":"Geisbert","year":"2011","journal-title":"J Infect Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"9875","DOI":"10.1128\/JVI.01147-15","article-title":"Temporal characterization of marburg virus angola infection following aerosol challenge in rhesus macaques","volume":"89","author":"Lin","year":"2015","journal-title":"J Virol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/s41598-017-01032-8","article-title":"Transcriptomic analysis reveals a previously unknown role for CD8+ T-cells in rVSV-EBOV mediated protection","volume":"7","author":"Menicucci","year":"2017","journal-title":"Sci Rep."},{"key":"B29","doi-asserted-by":"publisher","first-page":"9865","DOI":"10.1128\/JVI.01142-15","article-title":"Transcriptional profiling of the immune response to marburg virus infection","volume":"89","author":"Connor","year":"2015","journal-title":"J Virol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/S1473-3099(17)30541-8","article-title":"Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report","volume":"17","author":"Gsell","year":"2017","journal-title":"Lancet Infect Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.cell.2015.01.041","article-title":"Structural basis for Marburg virus neutralization by a cross-reactive human antibody","volume":"160","author":"Hashiguchi","year":"2015","journal-title":"Cell"},{"key":"B32","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1128\/CVI.00733-14","article-title":"Next-generation sequencing reveals a controlled immune response to Zaire Ebola virus challenge in cynomolgus macaques immunized with vesicular stomatitis virus expressing Zaire Ebola virus glycoprotein (VSVDeltaG\/EBOVgp)","volume":"22","author":"Barrenas","year":"2015","journal-title":"Clin Vaccine Immunol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1186\/s12864-016-3060-0","article-title":"In vivo Ebola virus infection leads to a strong innate response in circulating immune cells","volume":"17","author":"Caballero","year":"2016","journal-title":"BMC Genomics"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.3389\/fimmu.2017.01372","article-title":"Transcriptome analysis of circulating immune cell subsets highlight the role of monocytes in Zaire Ebola Virus makona pathogenesis","volume":"8","author":"Menicucci","year":"2017","journal-title":"Front Immunol."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.03071\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T06:56:50Z","timestamp":1548226610000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.03071\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,22]]},"references-count":34,"alternative-id":["10.3389\/fimmu.2018.03071"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.03071","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.735022521.793559623","asserted-by":"object"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,22]]},"article-number":"3071"}}